≥80岁转移性去势抵抗性前列腺癌一线阿比特龙与恩扎卢胺疗效比较
该回顾性倾向评分加权队列研究比较了≥80岁mCRPC患者一线使用阿比特龙(AA)与恩扎卢胺的疗效与耐受性。恩扎卢胺组PSA缓解率更高(61.6% vs 43.8%,P<0.004),至进展时间更长(HR 0.66,95%CI 0.50-0.88,P=0.01),但剂量减少和因非进展原因停药率也更高。尽管减量,临床结局未受不利影响,提示剂量调整可能平衡毒性与耐受性。
要点
- ≥80岁mCRPC患者中,恩扎卢胺较阿比特龙提高PSA缓解率并延长至进展时间。
- 恩扎卢胺剂量减少率(44.8% vs 22.9%)和非进展停药率(40.8% vs 28.8%)显著更高。
- 减量未显著影响至PSA进展或至进展时间,支持剂量调整策略。
核心结论
- 尽管恩扎卢胺剂量减少和停药率更高,其PSA缓解率和至进展时间仍优于阿比特龙。
- 临床结局未因治疗暴露减少而受不利影响,剂量调整可能有助于平衡毒性与耐受性。
研究设计与样本
- 采用基于倾向评分的逆概率治疗加权,加权Cox比例风险模型评估疗效。
主要发现
- 恩扎卢胺组PSA缓解率61.6%,阿比特龙组43.8%(P<0.004)。
- 恩扎卢胺组至进展时间HR 0.66(95%CI 0.50-0.88,P=0.01),至PSA进展时间HR 0.73(95%CI 0.53-1.01,P=0.06)。
- 恩扎卢胺组剂量减少率44.8%,阿比特龙组22.9%(P>0.001);非进展停药率分别为40.8%和28.8%(P=0.04)。
- 恩扎卢胺剂量减少和停药最常见原因为疲乏(分别占30.4%和5.6%)。
临床怎么用
- 对于≥80岁mCRPC患者,恩扎卢胺可能提供更高的PSA缓解率和更长的至进展时间。
- 临床应密切监测恩扎卢胺相关疲乏,及时进行剂量调整以平衡疗效与耐受性。
局限性
- 回顾性研究设计可能存在选择偏倚和未测量混杂。
- 样本量有限,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) disproportionately affects the elderly. There is limited data assessing the efficacy and tolerability of abiraterone acetate (AA) versus enzalutamide in this population. OBJECTIVE: To compare the clinical efficacy and tolerability of AA versus enzalutamide in patients ≥ 80 years with mCRPC. DESIGN, SETTING AND PARTICIPANTS: A retrospective propensity-weighted comparative cohort study of first-line AA versus enzalutamide among patients with mCRPC aged ≥80 years. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Inverse probability treatment weights based on propensity scores were generated to assess the treatment effect of AA versus enzalutamide on time to PSA progression (TTPP), time to progression (TTP) (first of PSA/radiographic/clinical progression) and overall survival using a weighted Cox proportional hazards model. PSA response rate (PSA RR) was compared between groups using Χ2. RESULTS AND LIMITATIONS: One hundred fifty-three patients received AA, and 125 received enzalutamide. Enzalutamide was associated with higher PSA RR (61.6% vs 43.8%, P < 0.004), and TTP (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.50-0.88, P = 0.01) but not TTPP (HR 0.73, 95% CI 0.53-1.01, P = 0.06). There were significantly more dose reductions with enzalutamide (22.9% vs 44.8%, P > 0.001) but there was no interaction between median proportion of full dose received and TTPP or TTP for either drug. Rates of treatment discontinuation (for reasons other than progression) were also significantly different between AA and enzalutamide (28.8% vs 40.8%, respectively, P = 0.04). The most common reason for dose reductions and discontinuation of enzalutamide was fatigue (30.4% and 5.6%, respectively). CONCLUSIONS: Despite more dose reductions and a higher treatment discontinuation rate, enzalutamide was associated with a higher PSA RR and longer time to progression, than AA. Given that clinical outcomes were not adversely impacted by decreased treatment exposure, dose modification may be a useful treatment strategy to balance toxicity and tolerance.
引用
- Soleimani M, Zou K, Sunderland K, et al. Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study. Eur J Cancer. 2021. PMID: 34130153. doi:10.1016/j.ejca.2021.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。